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Abstract
Background: Graft-versus-host disease (GVHD) remains a major contributor to mortality and morbidity after
allogeneic stem-cell transplantation (allo-HSCT). The updated recommendations suggest that rabbit antithymocyte
globulin or anti-T-lymphocyte globulin (ATG) should be used for GVHD prophylaxis in patients undergoing
matched-unrelated donor (MUD) allo-HSCT. More recently, using post-transplant cyclophosphamide (PTCY) in the
haploidentical setting has resulted in low incidences of both acute (aGVHD) and chronic GVHD (cGVHD). Therefore,
the aim of our study was to compare GVHD prophylaxis using either PTCY or ATG in patients with acute myeloid
leukemia (AML) who underwent allo-HSCT in first remission (CR1) from a 10/10 HLA-MUD.
Methods: Overall, 174 and 1452 patients from the EBMT registry receiving PTCY and ATG were included.
Cumulative incidence of aGVHD and cGVHD, leukemia-free survival, overall survival, non-relapse mortality,
cumulative incidence of relapse, and refined GVHD-free, relapse-free survival were compared between the 2 groups.
Propensity score matching was also performed in order to confirm the results of the main analysis
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Results: No statistical difference between the PTCY and ATG groups was observed for the incidence of grade II–IV
aGVHD. The same held true for the incidence of cGVHD and for extensive cGVHD. In univariate and multivariate
analyses, no statistical differences were observed for all other transplant outcomes. These results were also
confirmed using matched-pair analysis.
Conclusion: These results highlight that, in the10/10 HLA-MUD setting, the use of PTCY for GVHD prophylaxis may
provide similar outcomes to those obtained with ATG in patients with AML in CR1.
Keywords: Post-transplant cyclophosphamide, Antithymocyte globulin, Matched unrelated donor, Acute myeloid
leukemia
Background
Graft-versus-host disease (GVHD) remains a major con-
tributor to mortality and morbidity after allogeneic stem-
cell transplantation (allo-HSCT) [1–3]. The pathogenesis
of acute GVHD (aGVHD) and chronic GVHD (cGVHD)
is complex [4, 5]. Acute GVHD is initiated when alloreac-
tive donor immune cells recognize immunologically dis-
parate antigens in the host. The risk of developing GVHD
depends on the degree of HLA match, recipient age, graft
source, underlying disease diagnosis, intensity of condi-
tioning regimen, and also on GVHD prophylaxis. The up-
dated recommendations suggest that rabbit antithymocyte
globulin or anti-T-lymphocyte globulin (ATG) should be
used for GVHD prophylaxis in patients undergoing
matched-unrelated donor (MUD) allo-HSCT [6]. This
recommendation is based on several high-level evidence
publications showing a decreased rate of both acute and
chronic GVHD [7–10]. However, ATG delays immune re-
constitution and is associated with more infections, espe-
cially viral [11–13]. On the other hand, post-transplant
cyclophosphamide (PTCY) is now well-established, suc-
cessful, and widely utilized for GVHD prophylaxis after
haploidentical allo-HSCT [14, 15]. The mechanism of
PTCY has been described as inducing preferential elimin-
ation and clonal deletion of alloreactive T cells [16, 17].
Moreover, there is evidence supporting regulatory T cell
importance in mediating long-term post-transplant toler-
ance and GVHD control with PTCY [18–20]. Since then,
PTCY has been applied in other settings, including HLA-
identical sibling or UD and mismatched unrelated donor
(MMUD) [21–24]. In the 9/10 MMUD setting, PTCY use
was described as effective anti-GVHD prophylaxis com-
pared to ATG and likely to provide better outcomes in
long-term disease control [25]. This increase in evidence
of the positive impact of PTCY, prompted us to evaluate
its practical clinical use in allo-HSCT with MUD.
In the current study, we retrospectively analyzed re-
sults of allo-HSCT transplantation using 10/10 MUD in
a homogenous population of acute myeloid leukemia
(AML) patients in first complete remission (CR1), com-
paring the outcomes of PTCY versus ATG as GVHD
prophylaxis.
Methods
This is a retrospective study from the Acute Leukemia
Working Party (ALWP) of the European Society for
Blood and Marrow Transplantation (EBMT), which is a
working group of more than 600 transplant centers,
mostly located in Europe, that are required to report an-
nually all consecutive transplantations and follow-up
data. Data from all EBMT centers are entered, managed,
and maintained in a central online database. There are
no restrictions on centers for reporting data, except for
those required by law on patient consent, data confiden-
tiality, and accuracy. Quality control measures include
several independent systems: confirmation of the validity
of the entered data by the reporting team, selective com-
parison of the survey data with MED-A data sets in the
EBMT registry database, cross-checking with the Na-
tional Registries, and regular in-house and external data
audits. Patients provide informed consent authorizing
the use of their personal information for research pur-
poses. Each patient provides consent for transplant ac-
cording to the ethical principles of the Declaration of
Helsinki. The study was approved by the Institutional
Review Board of the ALWP of the EBMT.
Eligibility criteria
In order to be included in this study, patients had to ful-
fill all of the following criteria: age ≥ 18 years; diagnosed
with AML and undergoing first HSCT in CR1; from a
10/10 MUD (patients and donors should have HLA A,
B, C, and DRB1 and DQB1 allelic typing performed).
Graft source of stem cells was the peripheral blood stem
cells (PBSC) or bone marrow (BM). In the ATG group,
allo-HSCT patients received 5 mg/kg of thymoglobulin.
All patients underwent transplantation between January
2010 and December 2017.
Definitions
Endpoints of the study were the cumulative incidence of
acute GVHD grade II–IV and chronic GVHD, leukemia-
free survival (LFS), overall survival (OS), refined GVHD-
free, relapse-free survival (GRFS), cumulative incidences
of relapse (RI), and non-relapse mortality (NRM). Acute
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GVHD was graded according to the modified Glucks-
berg criteria [26] and cGVHD according to the revised
Seattle criteria [27].
Engraftment was defined as achieving an absolute neu-
trophil count greater than or equal to 0.5 × 109/L for
three consecutive days. The probability of being alive
Table 1 Baseline characteristics of patients
N ATG PTCY Test p value
1452 174
Follow-up
Median time (IQR) mo 33.2 (17.6–52.7) 20.5 (6.9–32.6) < 0.001
Age at allo-HSCT
Median (range) [IQR] 56 (18.1–77.5) [44.3–62.6] 46 (18–74.2) [34.7–59.3] < 0.001
Year allo-HSCT
Median (range) [IQR] 2014 (2010–2017) 2016 (2010–2017) < 0.001
Time diagnosis to allo-HSCT
Median (range) [IQR] 5.4 (1.5–17.7) [4.4–6.6] 4.7 (1.8–17.9) [3.8–7.7] 0.1
AML
De novo 1206 (83.06%) 161 (92.53%) 0.001
secAML 246 (16.94%) 13 (7.47%)
Cytogenetics (MRC)
Good 59 (4.06%) 4 (2.3%) 0.19
Interm 740 (50.96%) 80 (45.98%)
Poor 291 (20.04%) 35 (20.11%)
NA/failed 362 (24.93%) 55 (31.61%)
Conditioning regimen
MAC 687 (47.31%) 76 (43.68%) 0.36
RIC 765 (52.69%) 98 (56.32%)
Gaft cell type
BM 143 (9.85%) 18 (10.34%) 0.84
PBSC 1309 (90.15%) 156 (89.66%)
Kanofsky performance score
< 90 331 (24.68%) 29 (16.76%) 0.02
≥ 90 1010 (75.32%) 144 (83.24%)
Missing 111 1
Patient sex
Male 759 (52.27%) 98 (56.32%) 0.31
Female 693 (47.73%) 76 (43.68%)
Female donor-male recipient 165 (11.41%) 26 (14.94%) 0.17
Patient CMV serostatus
Negative 499 (34.92%) 43 (25.15%) 0.011
Positive 930 (65.08%) 128 (74.85%)
Missing 23 3
Engraftement
Graft failure 12 (0.83%) 2 (1.16%) 0.65
Engrafted 1432 (99.17%) 170 (98.84%)
Missing 8 2
Abbreviations: allo-HSCT allogeneic stem cell transplantation, AML acute myeloid leukemia, ATG anti-thymocyte globulin, BM bone marrow, CMV cytomegalovirus,
Interm intermediary, IQR interquartile range, KPS Karnovsky Performance Status, MAC myeloablative conditioning regimen, PBSC peripheral blood stem cell, PTCY
posttransplantation cyclophosphamide, RIC reduced intensity conditioning regimen, secAML secondary acute myeloid leukemia
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without evidence of relapse or progression defined LFS.
OS was defined as the time from allo-HSCT to death,
regardless of the cause. Refined GRFS was defined as be-
ing alive with neither grade III–IV aGVHD nor severe
cGVHD nor disease relapse at any time point 15. Death
without evidence of relapse defined NRM [28].
The cytogenetic risk was defined according to the
MRC criteria 11. Performance status was graded accord-
ing to the Karnofsky Performance Status (KPS) scale and
was defined as poor when it was < 90%. The condition-
ing regimen was defined according to data reported by
the EBMT centers as myeloablative (MAC) or reduced-
intensity (RIC) according to the EBMT definition 12.
Statistical analysis
Median values, inter-quartiles ranges (IQR), and mini-
mum and maximum were used to express continuous
variables while frequencies and percentages were used
for categorical variables. Patient-, disease-, and
transplant-related variables of the groups were compared
using the chi-square or Fischer’s exact test for categor-
ical variables, and the Mann-Whitney test for continu-
ous variables [29].
Acute and chronic GVHD, RI, and NRM were calcu-
lated using the cumulative incidence estimator to ac-
commodate competing risks. For NRM, relapse was the
competing risk, and for RI, the competing risk was death
without relapse. To study acute and chronic GVHD, we
considered relapse and death to be competing events.
The probabilities of OS, LFS, and GRFS were calculated
using the Kaplan–Meier method. Univariate analyses
were done using Gray’s test for cumulative incidence
functions and the log-rank test for OS, GRFS, and LFS.
A Cox proportional hazards model was used for multi-
variate regression. All variables differing significantly be-
tween the two groups, or variables deemed conceptually
important were included in the Cox model: ATG versus
PTCY, age, year of transplant, time from diagnosis to
transplant, secondary versus de novo AML, cytogenetics,
KPS, conditioning regimen, female donor to male recipi-
ent versus other, stem cell source, CMV serology status
for both patients, and donors. In order to test for a cen-
ter effect, we introduced a random effect or frailty for
each center into the model [30, 31]. Results were
expressed as the hazard ratio (HR) with the 95% confi-
dence interval (95% CI). P values were two-sided. Pro-
pensity score matching was also performed in order to
confirm the results of the main analysis 19. Each patient
identified as having received PTCY was matched with
two patients who had received ATG. The following fac-
tors were included in the propensity score model: age,
time from diagnosis to transplant, secondary AML,
Table 2 Cumulative incidence of GVHD
180-day acute GVHD II–IV 180-day acute GVHD III–IV 2-year chronic GVHD 2-year ext. chronic GVHD
PTCY 28.8% [22.2–35.7] 8.8% [5.1–13.7] 31.4% [23.3–39.8] 18.5% [12–26.1]
ATG 29.2% [26.8–31.6] 9% [7.6–10.6] 33.6% [31–36.2] 13.1% [11.2–15]
p value 0.68 0.89 0.43 0.11
Abbreviations: ATG antithymocyte globulin, Ext extensive, GVHD graft-versus host disease, PTCY post-transplantation cyclophosphamide
Table 3 Multivariate analysis for GVHD
Acute GVHD II–IV Acute GVHD III–IV Chronic GVHD Ext. chronic GVHD
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
ATG vs PTCY 0.98 (0.66–1.46) 0.93 0.84 (0.42–1.71) 0.64 1.22 (0.79–1.87) 0.37 0.64 (0.37–1.09) 0.09
Age (per 10 years) 1 (0.91–1.09) 0.92 1.01 (0.86–1.18) 0.92 1.06 (0.97–1.16) 0.20 1.03 (0.89–1.18) 0.73
sec. AML vs de novo 1.23 (0.95–1.61) 0.12 1.26 (0.79–2) 0.34 1.01 (0.76–1.33) 0.96 1.62 (1.1–2.39) 0.01
Adverse cytogenetics vs other 0.94 (0.74–1.21) 0.65 1.12 (0.73–1.71) 0.60 0.73 (0.56–0.96) 0.03 0.61 (0.39–0.95) 0.03
Female donor-male recipient vs other 1.27 (0.96–1.68) 0.10 1.67 (1.05–2.66) 0.03 1.07 (0.79–1.45) 0.65 1.05 (0.66–1.67) 0.83
RIC vs MAC 0.79 (0.62–1) 0.046 0.89 (0.59–1.36) 0.60 0.97 (0.76–1.23) 0.79 0.78 (0.54–1.14) 0.20
KPS ≥ 90 0.83 (0.65–1.06) 0.13 0.64 (0.42–0.97) 0.03 0.91 (0.71–1.17) 0.45 0.92 (0.63–1.34) 0.67
Patient CMV positivity 1.05 (0.85–1.31) 0.64 1.01 (0.68–1.48) 0.98 1.28 (1.03–1.6) 0.03 1.05 (0.75–1.47) 0.77
Donor CMV positivity 1 (0.81–1.23) 0.99 1.06 (0.73–1.53) 0.77 0.97 (0.79–1.2) 0.80 1.32 (0.96–1.82) 0.09
Year of transplantation 1.01 (0.96–1.06) 0.75 1.03 (0.94–1.12) 0.57 1 (0.95–1.05) 0.94 1.07 (0.99–1.16) 0.09
PBSC vs BM 1.05 (0.75–1.47) 0.77 1.1 (0.6–2) 0.76 1.1 (0.78–1.55) 0.59 1.37 (0.79–2.4) 0.26
Abbreviations: aGVHD acute graft-versus-host disease, AML acute myeloid leukemia, ATG antithymocyte globulin, BM bone marrow, CI confidence interval, CMV
cytomegalovirus, cGVHD chronic graft-versus-host disease, Ext extensive, HR hazard ratio, KPS Karnofsky Performance Status, MAC myeloablative conditioning
regimen, PBSC peripheral blood stem cells, PTCY post-transplantation cyclophosphamide, RIC reduced intensity conditioning regimen, sec. AML secondary acute
myeloid leukemia
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cytogenetics, conditioning intensity, female donor to
male recipient, patient, and donor CMV serology status.
All tests were two-sided. The type I error rate was fixed
at 0.05 for the determination of factors associated with
time-to-event outcomes. Statistical analyses were per-
formed with the SPSS 24 (SPSS Inc./IBM, Armonk, NY,
USA) and R 3.6.2 (R Development Core Team, Vienna,
Austria) software packages.
Results
The baseline characteristics are summarized in Table 1.
Overall, 174 and 1452 patients receiving PTCY and
ATG, respectively, fulfilled the inclusion criteria. The
median follow-up period was 20.5 (IQR 6.9–32.6)
months in the PTCY group as compared to 33.2 (17.6–
52.7) months in the ATG group (p < 0.001). Patients in
the PTCY group were younger (median age 46 versus 56
years, p < 0.001) and had undergone allo-HSCT more
recently (median year of allo-HSCT 2016 versus 2014, p
< 0.001). Time from diagnosis to allo-HSCT was similar
in both groups. Peripheral blood stem cells were the
more frequently used stem cell source, with no signifi-
cant difference of utilization among the 2 groups. Condi-
tioning regimen intensity was comparable in the two
groups. The only ATG brand used was Thymoglobu-
line®. Two or three additional immunosuppressive agents
were used in 55% and 85% of patients receiving PTCY
and ATG, respectively (supplementary data, Table S1).
Comparative analysis of transplant outcomes with ATG or
PTCY
The results of uni- and multivariate analyses are summa-
rized in Tables 2, 3, and 4. No statistically significant differ-
ences were observed between the PTCY and ATG groups
for RI, NRM, LFS, OS, and GRFS (Fig. 1). These results were
confirmed using matched-pair analysis (Tables S2 and S3).
Engraftment and GVHD
The proportion of patients achieving neutrophil engraft-
ment at 100 days was similar in the PTCY and ATG
groups (98.8% versus 99.2%, respectively, p = 0.65). The
median time to neutrophil engraftment was 21 and 18
days in PTCY and ATG groups, p < 0.001.
There were no significant differences in CI at 100 days
of aGVHD (grades II–IV or III–IV), cGVHD, or ext
cGVHD between the PTCY and the ATG group (Table
2) (Fig. 2). In the Cox model and in propensity score
(data not shown), there was not a significant statistical
difference between both groups, considering aGVHD II-
IV, aGVHD III-IV, cGVH, and extensive cGVHD.
Regardless of the use of PTCY or ATG, a RIC regimen
was independently associated with a lower risk of grade
II–IV acute GVHD, female donor to male recipient and
KPS < 90 associated with a higher risk of grade III–IV
acute GVHD and patient CMV positivity with a higher
risk of chronic GVHD (Table 3).
OS, LFS, and GRFS
On univariate analysis, there were no significant differ-
ences between the two groups with respect to OS, LFS,
or GRFS (Table 4). The GRFS was also similar, account-
ing for 42% in the PTCY and 49% in the ATG group (p
= 0.2) which results were also confirmed in the multi-
variate analysis (Table 5). Regardless of the use of PTCY
or ATG, a diagnosis of secondary AML and the presence
of adverse cytogenetics were associated with lower prob-
abilities of LFS, OS, and GRFS. Older age was also asso-
ciated with a lower OS and LFS.
Relapse incidence and NRM
The 2-year RI and NRM rates did not differ between the
two groups at 2 years. This was confirmed in the multi-
variate analysis where, regardless of the immunosuppres-
sive agent used, adverse cytogenetics at diagnosis was
independently associated with a higher risk of relapse.
Female donor to male recipient transplants were associ-
ated with a lower risk of relapse. Older age, secondary
AML patients, and transplants from a female donor to a
male recipient were independently associated with a
higher NRM (Table 5).
The main cause of death was disease recurrence in
47% of patients receiving PTCY and 39% of those receiv-
ing ATG. Infection accounted for 17% of deaths in the
PTCY group and 22% of the ATG group. Cardiac tox-
icity was fatal for 1.9% of patients who received PTCY
and 1.2% who received ATG (results not shown).
Discussion
We have compared the impact of PTCY with that of
ATG, (Thymoglobulin), in the conditioning regimen for
patients undergoing transplantation from 10/10 MUD.
First, we observed that PTCY and ATG had comparable
Table 4 Two-year survival outcomes
Relapse NRM LFS OS GRFS
PTCY 25.2% [18–32.9] 15.2% [9.7–21.8] 59.7% [50.6–67.6] 62.7% [53.4–70.7] 41.6% [33–50]
ATG 23.7% [21.4–26] 16.7% [14.8–18.8] 59.6% [56.8–62.2] 64.8% [62.1–67.4] 49.3% [46.6–52.1]
p value 0.6 0.6 0.97 0.95 0.2
Abbreviations: ATG antithymocyte globulin, GRFS GVHD-free, relapse-free survival, LFS leukemia-free survival, OS overall survival, NRM non-relapse mortality, PTCY
posttransplantation cyclophosphamide
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Fig. 1 Non-relapse mortality (NRM) (a), relapse incidence (RI) (b), leukemia-free survival (LFS) (c), overall survival (OS) (d), graft-versus-host
diseasefree, and relapse-free survival (GRFS) (e)
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cumulative incidences of aGVHD II–IV and grades III–
IV with between 8 and 9% in each group. The impact
was also similar considering cGVHD and extensive
cGVHD. Considering ATG, these results were consistent
with randomized clinical trials evaluating the use of
ATG in HSCT from unrelated donors [7, 9, 10, 32, 33].
Most data about using PTCY in MUD are from studies
of intensive pre-transplant conditioning regimens and
mostly unmanipulated BM grafts. Luznik et al. reported
data from 117 patients with high-risk hematological neo-
plasms transplanted from HLA-matched-related donors
and MUDs after conditioning with busulfan and cyclo-
phosphamide [34]. At 2 years after transplantation, the
cumulative incidence of cGVHD for recipients of
Fig. 2 Cumulative incidence of GVHD. aGVHD (a) and cGVHD (b)
Table 5 Multivariate analysis for Relapse, NRM, LFS, OS, and GRFS
Relapse NRM LFS OS GRFS
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
ATG vs PTCy 0.93 (0.63–1.37) 0.71 1.04 (0.65–1.66) 0.86 0.98 (0.74–1.29) 0.86 0.94 (0.7–1.27) 0.71 0.89 (0.7–1.13) 0.35
Age (per 10 years) 1.01 (0.92–1.11) 0.9 1.37 (1.2–1.56) < 10–5 1.13 (1.05–1.22) 0.001 1.21 (1.12–1.32) < 10–5 1.06 (1–1.14) 0.07
sec. AML vs de
novo
1.14 (0.86–1.53) 0.36 1.39 (1.02–1.9) 0.04 1.24 (1.01–1.53) 0.04 1.29 (1.03–1.6) 0.02 1.25 (1.03–1.52) 0.02
Adverse
cytogenetics vs
other
1.77 (1.41–2.24) < 10–5 1.19 (0.88–1.61) 0.27 1.51 (1.26–1.81) < 10–5 1.42 (1.17–1.72) 0.0004 1.36 (1.15–1.61) 0.0003
Female donor-
male recipient vs
other
0.54 (0.36–0.8) 0.002 1.46 (1.04–2.05) 0.03 0.89 (0.69–1.15) 0.38 0.93 (0.71–1.22) 0.6 1.11 (0.89–1.38) 0.35
RIC vs MAC 1.06 (0.82–1.36) 0.66 0.84 (0.63–1.13) 0.25 0.97 (0.81–1.17) 0.75 0.91 (0.74–1.11) 0.33 0.98 (0.83–1.15) 0.77
KPS ≥ 90 1.16 (0.9–1.51) 0.26 0.85 (0.64–1.13) 0.27 1.02 (0.84–1.23) 0.86 0.98 (0.81–1.2) 0.87 0.96 (0.81–1.13) 0.60
Patient CMV
positivity
0.99 (0.79–1.24) 0.92 1.31 (0.99–1.73) 0.06 1.11 (0.93–1.32) 0.24 1.12 (0.93–1.35) 0.22 1.11 (0.95–1.29) 0.21
Donor CMV
positivity
1.17 (0.94–1.45) 0.16 1 (0.77–1.3) 0.98 1.09 (0.92–1.28) 0.33 1.09 (0.91–1.3) 0.34 1.11 (0.96–1.29) 0.16
Year of
transplantation
1.04 (0.99–1.1) 0.12 1 (0.94–1.07) 0.99 1.02 (0.98–1.07) 0.26 1.02 (0.98–1.07) 0.37 1.03 (1–1.07) 0.07
PBSC vs BM 0.96 (0.68–1.36) 0.82 1.29 (0.8–2.09) 0.29 1.05 (0.8–1.39) 0.73 1.11 (0.82–1.49) 0.50 1.14 (0.88–1.47) 0.31
Abbreviations: AML acute myeloid leukemia, ATG antithymocyte globulin, BM bone marrow, CI confidence interval, CMV cytomegalovirus, cGVHD chronic graft-
versus-host disease, Ext extensive, GRFS graft-versus-host disease-free, relapse-free survival, HR hazard ratio, KPS Karnofsky Performance Status, LFS leukemia-free
survival, MAC myeloablative conditioning regimen, NRM non-relapse mortality, OS overall survival, PBSC peripheral blood stem cell, PTCY post-transplantation
cyclophosphamide, RIC reduced intensity conditioning regimen, sec.AML secondary acute myeloid leukemia
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unrelated donor grafts was 11% (95% CI, 3–25%). It
should be noted that PTCY was the only GVHD prophy-
laxis used, and BM was the only graft source used. Rug-
geri et al. reported outcomes of 423 patients who
received PTCY alone or in combination with additional
drugs after HLA-matched sibling (N = 241) or MUD (N
= 182) transplants using MAC or RIC [24]. In their
study, 64% received PBSC. On multivariate analysis,
PBSC was associated with a significantly higher risk of
cGVHD and extensive cGVHD but had no impact on
the other outcomes. We did not find any impact of
source graft in our study; however, almost 90% of the
patients received PBSC. Our results suggest that PTCY
is an alternative to the recommended clinical practice of
ATG in MUD. One hypothesis is that the degree of dis-
parity between a recipient with a 10/10 HLA matched
unrelated donor is low and the effect of PTCY of minim-
izing other HLA major or minor histocompatibility mis-
matches is not needed in this situation.
The second point is the absence of a significant differ-
ence at 2 years, in terms of NRM, which was quite low in
both groups (16.7% and 15.2% for PTCY and ATG groups,
respectively). Due to the retrospective nature of the study,
we could not compare the CI of infections especially viral
infections. Indeed, the use of ATG has been associated
with EBV reactivation [9, 35]. The comparison between
PTCY and ATG on EBV reactivation should be evaluated
in prospective studies. In our study, however, the inci-
dence of death from infection was similar in the two
groups. Likewise, it would be of interest to report cardiac
complications especially in the PTCY group, noting, that a
similar incidence of death from cardiac failure was ob-
served in both of our groups. RI was not statistically differ-
ent in the two groups. Retrospective or non-randomized
studies have reported conflicting results on the impact of
ATG in the setting of RIC transplants. In particular,
higher doses of ATG have been associated with a higher
risk of relapse, thus leading to a decreased disease-free
survival [11, 36]. On the contrary, Baron et al. found that
the use of ATG was not significantly associated with a
higher risk of relapse in patients with AML who under-
went PBSC transplantation from HLA-identical siblings
after RIC in CR1 [37]. Two other studies of our group did
not find the impact of ATG on relapse even in high-risk
AML [38, 39]. Because of lack of statistical power, we
could not study the impact of PTCY or ATG with respect
to the conditioning regimen intensity; however, we de-
cided to include only patients who received a low dose of
ATG (5 mg/kg in total), which has not been associated
with a higher incidence of relapse [40, 41].
Conclusions
The use of PTCY for GVHD prophylaxis resulted in
similar outcomes to those seen with ATG for patients
who underwent allogeneic stem cell transplantation for
AML in CR1 with a 10/10 HLA-matched donor. The
impact of the number, type, and schedule of the associ-
ated immunosuppressive agents needs further investiga-
tion. Due to the retrospective nature and the limitations
of our analysis, including the schedule of ATG or PTCY
and the lack of aforementioned data (e.g., infections, dis-
ease biology), our results need to be confirmed by pro-
spective controlled studies. A precise knowledge of
specific morbidity induced by each type of prophylaxis
would be of great interest in clinical practice to aid the
choice between PTCY or ATG when considering comor-
bidities and infection risk. Our results do, however, pro-
vide further proof that both ATG and PTCY are valid
GVHD prophylactic strategies for transplants from 10/
10 HLA-MUD.
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